Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $60.0M initial senior secured term loan funded, with up to $80.0M additional discretionary borrowing.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $60.0M initial senior secured term loan funded, with up to $80.0M additional discretionary borrowing
- Net proceeds approximately $58.6M, used partly to repay Kreos’ $55.0M prior term loan
- Variable interest rate 11.5% minimum, capped at 15.0%, with 4.0% default-rate increase
- Maturity November 12, 2031, no scheduled amortization, but 3.25% exit fee and prepayment premiums increase refinancing costs
- 3,441,352 warrants issued at $0.6974 per share, creating potential dilution; additional warrants tied to future borrowings
Item 1.02 · Termination of a Material Definitive Agreement
- Kreos Term Loan Facility terminated alongside the new loan agreement on January 29, 2024
- Akebia’s obligations under the prior facility paid in full and discharged
- Kreos released security interests over Akebia and guarantor assets
- Termination removes the prior lender’s claims and collateral encumbrances, with replacement financing terms detailed under Item 1.01
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material agreement created a direct financial obligation
- Investor impact depends on the referenced agreement’s payment terms, amount, maturity and financing purpose
Item 3.02 · Unregistered Sales of Equity Securities
- Warrant terms described under Item 1.01 govern the unregistered equity issuance
- Potential shareholder dilution depends on warrant count, exercise price, and expiration terms disclosed under Item 1.01
Item 7.01 · Regulation FD Disclosure
- Press release announces execution of a Loan Agreement
- Financing terms and obligations require review of Exhibit 99.1
- New borrowing may affect liquidity, leverage and future financing flexibility
Item 8.01 · Other Events
- Debt repayment removes the Prior Loan Agreement from the company’s financing obligations
- Management expects existing cash and operating revenues to fund the current plan for at least two years
- Expected funding sources include product, royalty, supply and license revenues
- Two-year runway reduces near-term financing risk but remains dependent on revenue generation and execution
Item EX-99.1 · Exhibit EX-99.1
- $60 million senior secured tranche fully funded on November 12, 2026
- Proceeds repaid BlackRock’s $55 million loan facility in full
- Up to $80 million additional financing available at Symbiotic Capital’s discretion, preserving non-dilutive funding potential
- 60-month maturity and interest-only period, with principal due at maturity
- Variable interest rate at the greater of WSJ Prime plus 4.5% or 11.5%, increasing financing costs and secured-debt obligations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.